Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma

Maria Alsina; Tania Fleitas-Kanonnikoff

doi:10.1016/j.medj.2024.05.016

Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma

Med. 2024 Sep 13;5(9):1038-1040. doi: 10.1016/j.medj.2024.05.016.

Authors

Maria Alsina¹, Tania Fleitas-Kanonnikoff²

Affiliations

¹ Medical Oncology Department, Hospital Universitario de Navarra, Translational Medical Oncology Investigational Group, Navarrabiomed - IdiSNA, C/ Irunlarrea 3, 35008 Pamplona, Spain. Electronic address: [email protected].
² Medical Oncology Department, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain.

PMID: 39276766
DOI: 10.1016/j.medj.2024.05.016

Abstract

Immunotherapy has revolutionized the treatment landscape of esophageal squamous cell carcinoma. He et al. present the final results of the randomized phase 3 ESCORT-1st trial, confirming positive survival outcomes when adding the anti-PD1 inhibitor camrelizumab to first-line chemotherapy treatment in Chinese patients with esophageal squamous cell cancer.¹.

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Esophageal Neoplasms* / drug therapy
Esophageal Neoplasms* / immunology
Esophageal Neoplasms* / pathology
Esophageal Squamous Cell Carcinoma* / drug therapy
Esophageal Squamous Cell Carcinoma* / immunology
Esophageal Squamous Cell Carcinoma* / pathology
Humans
Immune Checkpoint Inhibitors* / pharmacology
Immune Checkpoint Inhibitors* / therapeutic use
Randomized Controlled Trials as Topic

Substances

Immune Checkpoint Inhibitors
camrelizumab
Antibodies, Monoclonal, Humanized